A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia-Reference-Cited by-同舟云学术

A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia

Published:2013-03 Issue:3 Volume:63 Page:496-503
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Marberger Michael,Chartier-Kastler Emmanuel,Egerdie Blair,Lee Kyu-Sung,Grosse Joachim,Bugarin Denise,Zhou Jihao,Patel Anand,Haag-Molkenteller Cornelia

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. BPH: epidemiology and comorbidities;McVary;Am J Manag Care,2006

2. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia;Fourcade;World J Urol,2012

3. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study;Maria;Urology,2003

4. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates;Chuang;Urology,2005

5. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia;Chuang;BJU Int,2006

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Botulinum toxin therapy in urology: historical aspect;Urology reports (St. - Petersburg);2024-08-08

2. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update;Expert Opinion on Emerging Drugs;2024-06-14

3. Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-06-05

4. Botulinumtoxin bei Symptomen des unteren Harntraktes beim Mann („male LUTS“): Was darf man erwarten?;Die Urologie;2024-05-02

5. Early investigational agents for the treatment of benign prostatic hyperplasia’;Expert Opinion on Investigational Drugs;2024-03-04